BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 7524906)

  • 1. Myeloma cell contamination of peripheral blood stem cell grafts in patients with multiple myeloma treated by high-dose therapy.
    Mariette X; Fermand JP; Brouet JC
    Bone Marrow Transplant; 1994 Jul; 14(1):47-50. PubMed ID: 7524906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of gene-marked CD34+ cells after autologous stem cell transplantation for multiple myeloma.
    Alici E; Björkstrand B; Treschow A; Aints A; Smith CI; Gahrton G; Dilber MS
    Cancer Gene Ther; 2007 Mar; 14(3):227-32. PubMed ID: 17082794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene scanning of VDJH-amplified segments is a clinically relevant technique to detect contaminating tumor cells in the apheresis products of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation.
    López-Pérez R; García-Sanz R; González D; Balanzategui A; Chillón MC; Alaejos I; Mateos MV; Caballero MD; Corral M; Orfão A; González M; San Miguel JF
    Bone Marrow Transplant; 2001 Oct; 28(7):665-72. PubMed ID: 11704789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Collection of peripheral blood progenitor cells for autografting with low-dose cyclophosphamide plus granulocyte colony-stimulating factor.
    Bellido M; Sureda A; Martino R; Madoz P; García J; Brunet S
    Haematologica; 1998 May; 83(5):428-31. PubMed ID: 9658727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer cell numbers and activity in mobilized peripheral blood stem cell grafts: conditions for in vitro expansion.
    Silva MR; Parreira A; Ascensão JL
    Exp Hematol; 1995 Dec; 23(14):1676-81. PubMed ID: 8542964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD34+ selection of autologous peripheral blood stem cells for transplantation following sequential cycles of high-dose therapy and mobilization in multiple myeloma.
    Dyson PG; Horvath N; Joshua D; Barrow L; Van Holst NG; Brown R; Gibson J; To LB
    Bone Marrow Transplant; 2000 Jun; 25(11):1175-84. PubMed ID: 10849530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leukapheresis products in multiple myeloma: lower tumor load after mobilization with cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) compared with G-CSF alone.
    Cremer FW; Kiel K; Wallmeier M; Haas R; Goldschmidt H; Moos M
    Exp Hematol; 1998 Sep; 26(10):969-75. PubMed ID: 9728932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of malignant B cells in peripheral blood stem cell collections after chemotherapy in patients with multiple myeloma.
    Dreyfus F; Ribrag V; Leblond V; Ravaud P; Melle J; Quarre MC; Pillier C; Boccaccio C; Varet B
    Bone Marrow Transplant; 1995 May; 15(5):707-11. PubMed ID: 7670399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts.
    Vescio RA; Han EJ; Schiller GJ; Lee JC; Wu CH; Cao J; Shin J; Kim A; Lichtenstein AK; Berenson JR
    Bone Marrow Transplant; 1996 Jul; 18(1):103-10. PubMed ID: 8832002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First and second apheresis in patients with multiple myeloma: no differences in tumor load and hematopoietic stem cell yield.
    Kiel K; Cremer FW; Ehrbrecht E; Wallmeier M; Hegenbart U; Goldschmidt H; Moos M
    Bone Marrow Transplant; 1998 Jun; 21(11):1109-15. PubMed ID: 9645573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood stem cell collection using chemotherapy with or without systematic G-CSF: experience in 52 patients with multiple myeloma.
    Lefrere F; Makke J; Fermand J; Marolleau J; Dal Cortivo L; Alberti C; Mouton V; Benbunan M; Miclea J
    Bone Marrow Transplant; 1999 Sep; 24(5):463-6. PubMed ID: 10482928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome.
    Patriarca F; Damiani D; Fanin R; Grimaz S; Geromin A; Cerno M; Sperotto A; Silvestri F; Zaja F; Baccarani M
    Haematologica; 2000 Mar; 85(3):269-74. PubMed ID: 10702815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.
    Weisdorf D; Miller J; Verfaillie C; Burns L; Wagner J; Blazar B; Davies S; Miller W; Hannan P; Steinbuch M; Ramsay N; McGlave P
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
    Engelhardt M; Winkler J; Waller C; Lange W; Mertelsmann R; Henschler R
    Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular detection of tumor contamination in peripheral blood stem cell harvests.
    Craig JI; Langlands K; Parker AC; Anthony RS
    Exp Hematol; 1994 Aug; 22(9):898-902. PubMed ID: 7914873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood.
    Gehling UM; Ryder JW; Hogan CJ; Hami L; McNiece I; Franklin W; Williams S; Helm K; King J; Shpall EJ
    Exp Hematol; 1997 Oct; 25(11):1125-39. PubMed ID: 9328449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and molecular follow-up by amplification of the CDR-III IgH region in multiple myeloma patients after autologous transplantation of hematopoietic CD34+ stem cells.
    Martinelli G; Terragna C; Lemoli RM; Cavo M; Benni M; Motta MR; Amabile M; Ottaviani E; Testoni N; de Vivo A; Tura S
    Haematologica; 1999 May; 84(5):397-404. PubMed ID: 10329917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of autografting using mobilized peripheral blood stem cells with and without granulocyte colony-stimulating factor in malignant lymphomas.
    Brice P; Divine M; Marolleau JP; Haioun C; Dalcortivo L; Sitthy X; Beaujean F; Norol F; Benbunan M; Reyes F
    Bone Marrow Transplant; 1994 Jul; 14(1):51-5. PubMed ID: 7524907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of minimal residual disease by polymerase chain reaction in B cell malignancies.
    Moos M; Schulz R; Cremer F; Sucker C; Schmohl D; Döhner H; Goldschmidt H; Haas R; Hunstein W
    Stem Cells; 1995 Dec; 13 Suppl 3():42-51. PubMed ID: 8747988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.